Back to Search
Start Over
Combined Posttransplant Prophylactic IVIg/Anti-CD 20/Plasmapheresis in Kidney Recipients With Preformed Donor-Specific Antibodies: A Pilot Study
- Source :
- Transplantation. 89:1403-1410
- Publication Year :
- 2010
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2010.
-
Abstract
- Background This study assesses the immunologic, functional, and histologic course of kidney recipients with preformed donor-specific alloantibodies (DSA) receiving deceased donor kidneys according to two prophylactic strategies that have been sequentially applied posttransplant. Methods The first strategy combined posttransplant quadritherapy/intravenous immunoglobulin (group 1, n=36) and the second added to the above protocol anti-CD20/plasmapheresis (group 2, n=18). All patients had a concomitant evaluation of glomerular filtration rate, protocol biopsies, and DSA mean intensity of fluorescence (MFI) at 3 month and 1 year posttransplant. Results Peak and day-0 class-I or II DSAmax-MFI were similar in both groups. The rate of acute antibody-mediated rejection (AMR) was similar in both groups (19.6% vs. 16.6%, respectively). At 1 year posttransplant, group 2 was characterized by lower microcirculation inflammation lesions (glomerulitis+capilaritis score of 1.8+/-0.2 vs. 2.7+/-0.2, respectively, P=0.03), a lower rate of transplant glomerulopathy (7% vs. 38%, P=0.02), and a lower rate of chronic AMR (41.3% vs. 13.3%, respectively, P=0.03). The decline in DSA-MFI from day 0 to 1 year was 44%+/-13% in group 1 compared with 80%+/-8% in group 2 (P=0.02). Finally, the 1-year glomerular filtration rate was 43+/-16 vs. 54+/-16 mL/min/1.73 m(2) in groups 1 and 2, respectively (P=0.04). Conclusion This study raises the possibility that a more intensive day 0 prophylactic immunosuppressive strategy combining intravenous immunoglobulin/anti-CD20/plasmapheresis in this high-risk population, despite similar rates of early acute clinical humoral rejection, is associated with significant differences in long-term function and chronic AMR rate. Future prospective randomized studies are needed to assess the best strategies to be applied in light of the pretransplant immunologic risk stratification.
- Subjects :
- Graft Rejection
medicine.medical_specialty
medicine.medical_treatment
Urinary system
Calcineurin Inhibitors
Population
Renal function
Pilot Projects
Risk Assessment
Gastroenterology
Antibodies, Monoclonal, Murine-Derived
Postoperative Complications
Isoantibodies
Internal medicine
medicine
Humans
Immunologic Factors
education
Retrospective Studies
Transplantation
education.field_of_study
business.industry
Microcirculation
Graft Survival
Antibodies, Monoclonal
Immunoglobulins, Intravenous
Transplant glomerulopathy
Plasmapheresis
Mycophenolic Acid
Antigens, CD20
medicine.disease
Combined Modality Therapy
Kidney Transplantation
Tissue Donors
Surgery
Concomitant
Rituximab
business
Immunosuppressive Agents
Glomerular Filtration Rate
medicine.drug
Subjects
Details
- ISSN :
- 00411337
- Volume :
- 89
- Database :
- OpenAIRE
- Journal :
- Transplantation
- Accession number :
- edsair.doi.dedup.....b5076e4d49b0d5a5920f6c78395bf6f7
- Full Text :
- https://doi.org/10.1097/tp.0b013e3181da1cc3